Biotechnology

CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia

SUZHOU, China, Dec. 12, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received the approval from the Human Research Ethics Committee (HREC) in Australia, and the acknowledgement from Australia's Therapeutic Goods ...

2019-12-12 14:47 167

Biocon Biologics Symposium on '100 Years of Insulin - Delivering on Universal Access & Equitable Care' Resonates Well With Leading KOLs at IDF Congress 2019

BENGALURU, India, Dec. 12, 2019 /PRNewswire/ -- Biocon Biologics, a fully integrated 'pure play' global biosimilars organisation, brought together Key Opinion Leaders (KOLs), including physicians, scientists, healthcare professionals, government representatives, policy makers, and IDF members, at...

2019-12-12 09:00 253

Human Microbiome Market to Reach $6.08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics

SANTA CLARA, California, Dec. 11, 2019 /PRNewswire/ -- There has been a surge in industry-academia collaborations in thehuman microbiome therapeutics space. The partnerships betweenpharma/biotech companies and academic institutes are bringing together the research expertise of educational organiz...

2019-12-11 23:55 293

AGC Biologics Expands Plasmid DNA Offering

SEATTLE, Dec. 11, 2019 /PRNewswire/ -- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from itsHeidelberg site in Germany. With the demand for pDNA growing rap...

2019-12-11 09:06 266

Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...

2019-12-11 08:41 1245

Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"

SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results ...

2019-12-11 08:00 245

Publication of First In-Human Data Reveals Safety & Efficacy of Tigilanol Tiglate in Solid Tumours

* First in-human Clinical Phase I study of intratumoural tigilanol tiglate (EBC-46) has been published in The Lancet's EBioMedicine journal; * An efficacious dose was achieved and a Maximum Tolerated Dose (MTD) was not reached, indicating tigilanol tiglate tolerability in humans; * Promising...

2019-12-09 21:01 387

PRC NHC Issues New Policy on Cord Blood Banks, Implementation Rules To Be Provided

HONG KONG, Dec. 6, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today reported thatChina's National Health Commission ("NHC") ...

2019-12-06 20:00 5345

Global Cord Blood Corporation Announces Results of 2019 Annual General Meeting

HONG KONG, Dec. 5, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2019 Annual Gene...

2019-12-05 21:30 5656

Hummingbird Bioscience Raises US$19 Million in Series B Financing

SINGAPORE, Dec. 5, 2019 /PRNewswire/ -- Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery and development of new breakthrough precision antibody therapeutics for difficult-to-treat conditions, today announced that it has raisedUS$19 million in a Series B finan...

2019-12-05 10:00 528

Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine

Newly updated and expanded NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic clarify who should be tested for cancer-causing genetic mutations Experts caution about risks of direct-to-consumer genetic testing and stress the importance of genetic counselin...

2019-12-04 22:01 417

PathogenDx Lauded by Frost & Sullivan for Its Game-changing DNA-based Multiplex Microarray Technology

PathogenDx's breakthrough technology shifts the pathogen detection paradigm from microbial to molecular testing through its microarray assays, namely Detect X, EnviroX, and QuantX SANTA CLARA, California, Dec. 3, 2019 /PRNewswire/ -- Based on its recent analysis of the global microbial DNA testin...

2019-12-03 22:00 329

QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer

* First patient successfully dosed in QBiotics' Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) * Tigilanol tiglate is a novel, small molecule that is being tested as a single injection treatment for solid tumours * The Phase I/II ...

2019-12-03 07:11 459

Gowan Company Announces Acquisition of Two New Active Ingredients, Fenamidone and Pencycuron, from Bayer AG

HARPENDEN, England, Dec. 3, 2019 /PRNewswire/ -- Gowan Crop Protection Limited, an affiliate of Gowan Company, L.L.C., announced today that it has entered into agreements with Bayer AG to acquire  rights to the active ingredients Fenamidone and Pencycuron.  The acquisition includes product regist...

2019-12-03 01:00 477

CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset

* The newly founded relationship will combine the research and development ingenuity of Fapon Biopharma with the state-of-art biologics manufacturing services offered by CMAB * CMAB will provide a full range of development and manufacturing services for Fapon Biopharma's biologic drug project...

2019-12-02 18:28 374

Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL)

SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced...

2019-11-28 12:10 1147

Golden Meditech Announces FY2019/2020 Interim Results

Revenue Fluctuated Amidst the Challenging Market Conditions Significant Increase in Revenue Noted at Beijing Sunbow Obstetrics & Gynecology Hospital HONG KONG, Nov. 27, 2019 /PRNewswire/ -- For the Six Months Ended 30 September 2019 (HK$'000) 2018 (HK$'000) Change (%) Revenue 157,2...

2019-11-27 18:52 1233

Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2020

HONG KONG, Nov. 27, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for...

2019-11-27 05:16 10017

New Study by TauRx Shows a Minimum Dose of Hydromethylthionine Could Slow Cognitive Decline and Brain Atrophy in Mild-to-moderate Alzheimer's Disease

ABERDEEN, Scotland and SINGAPORE, Nov. 27, 2019 /PRNewswire/ -- In a paper published in today's online issue of theJournal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels ...

2019-11-27 02:31 486

Japan and Singapore Grant CRISPR Patents to Merck

- Merck now holds 22 CRISPR-related patents worldwide across nine different geographies - Patents cover Paired Cas9 Nickase CRISPR genome-editing technology to advance gene therapy and research DARMSTADT, Germany, Nov. 26, 2019 /PRNewswire/ -- Merck, a leading science and technology company, to...

2019-11-26 21:00 349
12345 ... 54